BCDAD - BioCardia, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
10.00
0.00 (0.00%)
At close: 10:17AM EDT
Stock chart is not supported by your current browser
Previous Close10.00
Open10.00
BidN/A x N/A
AskN/A x N/A
Day's Range10.00 - 10.00
52 Week Range7.29 - 32.22
Volume100
Avg. Volume539
Market Cap48.48M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    BioCardia Announces Reverse Stock Split and Plan for Listing on a Major Stock Exchange

    BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that a reverse stock split of its common stock, $0.001 par value, at a ratio of one-for-nine, is effective today, June 6, 2019.  The Company’s common stock will begin trading on a split adjusted basis when the markets open under the new trading symbol (BCDAD) and in 20 business days, the trading symbol will revert back to our existing symbol, “BCDA”.  The Company’s common stock has been assigned a new CUSIP number of 09060U507 in connection with the reverse stock split. As a result of the reverse split, each nine pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 43.6 million shares to approximately 4.8 million shares.  The reverse stock split will also apply to common stock issuable upon the exercise of the Company’s outstanding stock options and warrants for common stock.  There is no change to the number of authorized shares under the Company’s Certificate of Incorporation, as amended.  The common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable.  The reverse stock split will not affect the par value of the common stock.

  • We're sorry this is all we were able to find about this topic.